Drug Profile
Research programme: endothelial cell therapy (PVS 30200) - Takeda
Alternative Names: Cancer cell therapy (PVS-30200); Cell-based oncology programme (PVS-30200) - Takeda; Matrix-embedded endothelial cell-based therapy (PVS-30200) - Takeda; PVS-30200Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Pervasis Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours; Wounds
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Wounds in USA